Revlon. O’Neal and Jones formed OJF Pharmaceutical Sales company, which in 1978, was acquired by Chromalloy American Corporation. Jones Pharma Dennis and Judy Jones gathered their entire savings, $100,000, along with an additional $200,000 from friends, and founded Jones Medical, later renamed Jones Pharma, on March 16, 1981. The idea was to purchase products and companies, eliminate duplicate overhead, and make profitable acquisitions. Jones Pharma looked for products large companies didn't have time to promote – successful products that, with some aggressive marketing, could prove to be extremely profitable. In the process of starting Jones Pharma, Dennis is credited with creating a new business model: the emerging specialty pharmaceutical group which has since been copied by other companies. In the beginning, Jones Pharma consisted of Dennis and Judy Jones and one other employee. Within two years, two of his brothers joined (they later left for other ventures), and the company began making acquisitions. At its pinnacle, Jones Pharma employed 600 people in five plants located in Phoenix, Arizona, St. Petersburg, Florida, Canton, Ohio, Madison, Wisconsin, and St. Louis, Missouri. By 1999, they had made 19 acquisitions. Jones acquired a product named Thrombin USP, a hemostat that acts as a clotting agent in surgery. They tenaciously marketed the product and it wasn't long before sales of Thrombin surpassed similar products at Parke Davis and Johnson & Johnson, eventually driving both out of the market. The company completed its initial public offering in 1986, trading under the ticker symbol JMED on the NASDAQ. For a decade in the 1990s, with Dennis as the Chairman and CEO, Jones Pharma's return to investors was the largest of any pharmaceutical company and the second largest on Wall Street. In the summer of 2000, the Joneses decided to sell the company to King Pharmaceuticals, based in Bristol, TN for $3.4 billion, an all-time record price for a company with annual sales of $200 million. According to public filings, the vast majority of the company sales proceeds were realized by the company's 600 employees and other public shareholders. Jones initiated one of the first employee stock option programs in the pharmaceutical industry. Post business life After selling Jones Pharma, the Joneses retired in Ladue, a suburban St. Louis community. In 2014, Dennis and Judy Jones ordered the build of a $34 million, 164 ft. motor yacht – D’Natalin IV - by U.S. yacht builder, Christiansen Yachts. Jones